In this pilot study the investigators shall prospectively in a blinded fashion evaluate with Aβ PET in patients committed to shunt surgery and then investigate the relationship of these biomarkers with outcome on gait, cognition and urinary control improvement in the short term (3 months) and long term (1 year). The imaging agent will be provided by AVID. Furthermore the study will standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden.
Study Type
OBSERVATIONAL
Enrollment
2
Mayo Clinic
Jacksonville, Florida, United States
Comparison of change between florbetapir +ve and -ve patients from baseline to one year in the Montreal Cognitive Assessment (MoCA)
Time frame: Baseline to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.